Previous Article | Next Article 
Journal of Clinical Microbiology, October 2008, p. 3510-3513, Vol. 46, No. 10
0095-1137/08/$08.00+0 doi:10.1128/JCM.01512-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Dynamics of the Mucosa-Associated Flora in Ulcerative Colitis Patients during Remission and Clinical Relapse
,
Stephan J. Ott,1,2,
Sophie Plamondon,3,
Ailsa Hart,3
Alexander Begun,1,4
Ateequr Rehman,2
Michael A. Kamm,3,
* and
Stefan Schreiber1,2,
*
Institute for Clinical Molecular Biology, Christian Albrechts University Kiel, Schittenhelmstr. 12, 24105 Kiel, Germany,1
Clinic for General Internal Medicine, University Hospital Schleswig-Holstein, Campus Kiel, Schittenhelmstr. 12, 24105 Kiel, Germany,2
St. Mark's Hospital, Watford Road, Harrow, HA1 3UJ Middlesex, London, United Kingdom,3
Institute for Medical Informatics and Statistics, Christian Albrechts University Kiel, Brunswikerstr. 10, 24105 Kiel, Germany4
Received 6 August 2008/
Accepted 7 August 2008

ABSTRACT
The colonic mucosa-associated flora (MAF) in patients with active
ulcerative colitis (UC) (
n = 13) was investigated by examining
16S rRNA gene signatures during remission and relapse against
levels for controls (
n = 5). Baseline reduction, temporal instability,
and decrease of bacterial richness toward relapse were observed
for UC patients, whereas the MAF for controls was stable over
time.

TEXT
Microbial studies have shown a persistent reduction in biodiversity
of the mucosa-associated flora (MAF) in patients with active
inflammatory bowel disease compared with the MAF in normal and
non-inflammatory bowel disease inflammatory controls (
2). A
loss of normal anaerobic components (
Bacteroides,
Eubacterium,
and
Lactobacillus spp.) has contributed to this difference (
7,
11). A shift to an increased representation of gram-negative
bacteria appears to accompany a reduced bacterial diversity
in Crohn's disease patients during remission, suggesting that
these abnormalities may be primary and not secondary to the
inflammatory process (
4). We have conducted a prospective study
of the MAF in patients with ulcerative colitis (UC) during remission
to investigate temporal changes in bacterial richness and diversity.
Monthly biopsy specimens were obtained during a 1-year follow-up.
Follow-up was terminated if patients developed a clinical relapse.
The 1-year prospective follow-up protocol was conducted at St. Mark's Hospital, Harrow, United Kingdom. The patients included had established UC confirmed by clinical, endoscopic, and histological features and had frequently relapsing disease (defined as at least two episodes requiring medical treatment in the past 12 months). Clinical characteristics are given in Table 1. Inclusion criteria allowed concurrent medication with oral 5-aminosalicylates (5-ASA) at a stable dose for at least 4 weeks and azathioprine or 6-mercaptopurine at a stable dose for at least 3 months prior to screening. Treatments with steroids, antibiotics, anti-tumor necrosis factor agents, and rectal 5-ASA were not permitted for a minimum of 4 weeks before or at any time during the study. The UC disease activity index (UCDAI) was used for assessment of disease activity (8). At enrollment, patients were in remission, defined as a UCDAI of 1 or 0 and an endoscopic subscore of 0 (normal mucosal appearance). Following screening, UC patients attended monthly study visits until relapse or for a maximum of 12 months. Relapse was defined as a UCDAI of greater than 3, including an endoscopic score of at least 1 (mucosal friability). Five healthy volunteers were included for benchmarking the assessments (Table 2). Specimens from these controls were collected at two time points (0 and 6 months) from the same location. No colonic cleansing with oral agents or enemas was used. All laboratory investigations were carried out at the Institute for Clinical Molecular Biology in Kiel, Germany. The research protocol was approved by the ethics committee of the Medical Faculty of Christian Albrechts University in Kiel. PCR, single-stranded conformation polymorphism analysis, cloning, and sequencing of bands, including sequence analysis, were performed as described earlier (5, 6, 7). For comparison of remission status and relapse status in UC, a total of 43 bands were included in the statistical analysis. Standard statistical tests were conducted using SPSS (10.0; Chicago, IL). To investigate the regularities of the bacterial dynamics in individuals with UC, information on the intensity levels of 43 bacterial bands for the 13 patients were used. These multidimensional data were treated using methods of the analysis of neural networks (9) (see the supplemental material). These measurements are based on community fingerprint profiles of bacterial consortia of monthly biopsy specimens taken after initial induction of remission until the moment of relapse. The time to relapse, in months, is given in Table 1.
A total of 43 different band classes were identified for UC
patients and 61 band classes for controls, corresponding to
a baseline reduction in bacterial richness by 15% in UC patients
at study start in comparison to levels for normal controls.
One band of each class was excised, cloned, and sequenced. Sequencing
of the 61 band classes resulted in taxonomic results from 53
bands, while 8 gave no reproducible results. The overall richness
of bacterial operational taxonomic units (OTUs) as revealed
by BLAST analysis is shown in Table
3. A total of 91 different
OTUs were identified from the 53 band classes, including 17
(18.7%) sequences assigned to uncultured bacteria. As indicated
in Fig.
1A, a significant reduction of bands was seen for UC
patients between remission and relapse in comparison with repeated
sampling of controls at the two different time points (25.31
versus 18.38 for UC patients, 38.4 versus 36.4 for the control
sample,
P = 0.031). A similar change in diversity scores was
seen (Fig.
1B). No specific OTUs that would predict the time
point of relapse were found during remission (i.e., at study
start). Densitometric intensities of matched bands for the UC
patients were pairwise compared between enrollment and time
of relapse by use of a Wilcoxon matched-paired signed-rank test.
For five bands, a significant difference was seen (
P = 0.011),
due to a reduction of the bacterial OTUs listed in Table
4.
As shown, the decrease in bacterial complexity at relapse that
was observed was due to a loss of normal intestinal bacterial
taxa, such as
Bacteroides,
Escherichia,
Eubacterium,
Lactobacillus,
and
Ruminococcus spp. In comparison with the repeat biopsy specimens
from normal controls, bacterial communities in specimens from
patients with UC during remission showed variation in richness
and diversity over time. Unfortunately, the relapse biopsy specimen
endpoint was reached at month 2 for four patients and at month
3 for six patients (one patient lost to follow-up at month 3).
One patient stayed in remission until month 4.
The loss of commensal organisms could profoundly modify gut
mucosal homeostasis through a loss of essential micronutrients
and redox potential (e.g., short-chain fatty acids) (
1). A further
decrease of microbial diversity therefore not only could be
a marker of relapse in UC but might be a causative factor driving
the inflammatory change. Gut microbiota in normal individuals
are remarkably stable over time (
12,
13). Although the study
was hampered by the early relapse that most patients developed,
it appears that UC is associated with a high degree of instability
in richness and diversity of the MAF. The inability to find
specific changes in the microbial composition to predict relapse
or to detect a temporal interaction between different species
of the MAF may result from a lack of power due to the limited
observation time with the small number of patients. Larger consecutive
series, including long-term remission studies, are necessary
to investigate this question. There is a significant decrease
in diversity and richness of the MAF of patients with UC in
remission compared to that of controls, and a further decrease
in diversity was observed at relapse. In particular, the decrease
in bacterial complexity at relapse that was observed was due
to a loss of normal intestinal bacterial taxa, such as
Bacteroides,
Escherichia,
Eubacterium,
Lactobacillus, and
Ruminococcus spp.
The composition of MAF in UC patients appears to be remarkably
unstable. Further studies will investigate treatment outcome
and long-term courses of remission to examine a putative link
between MAF and the pathophysiology of active disease for UC.

ACKNOWLEDGMENTS
We acknowledge funding through the BMBF (Competence Network
IBD, National Genome Research Network, and Infectious Disease
Network), DFG, and MFG.
S.S. declares competing financial interests as a speaker for SigmaTau (makers of VSL#3) and a member of the scientific advisory board for Applied Biosystems, an Applera corporation.

FOOTNOTES
* Corresponding author. Mailing address for Michael A. Kamm: St. Mark's Hospital, Watford Road, Harrow HA1 3UJ, United Kingdom. Phone: 0044 20 8235 4160. Fax: 0044 20 8235 4162. E-mail:
kamm{at}ic.ac.uk. Mailing address for Stefan Schreiber: Clinic for General Internal Medicine, UKSH, Campus Kiel, and Institute for Clinical Molecular Biology, CAU Kiel, Schittenhelmstr. 12, 24105 Kiel, Germany. Phone: 0049 431 597 2350. Fax: 0049 431 597 1434. E-mail:
s.schreiber{at}mucosa.de 
Published ahead of print on 13 August 2008. 
Supplemental material for this article may be found at http://jcm.asm.org/. 
These authors contributed equally to the work. 
These authors contributed equally to the work. 

REFERENCES
1 - Blaut, M., and T. Clavel. 2007. Metabolic diversity of the intestinal microbiota: implications for health and disease. J. Nutr. 137:751S-755S.[Abstract/Free Full Text]
2 - Hart, A. L., A. J. Stagg, M. Frame, H. Graffner, H. Glise, P. Falk, and M. A. Kamm. 2002. The role of the gut flora in health and disease, and its modification as therapy. Aliment. Pharmacol. Ther. 16:1383-1389.[CrossRef][Medline]
3 - Holt, J. G. (ed.). 1994. Bergey's manual of determinative bacteriology, 9th ed. Williams & Wilkins, Baltimore, MD.
4 - Manichahn, C., L. Rigottier-Gois, E. Bonnaud, K. Gloux, E. Pelletier, L. Frangeul, R. Nalin, C. Jarrin, P. Chardon, P. Marteau, J. Roca, and J. Dore. 2006. Reduced diversity of faecal microbiota in Crohn's disease revealed by metagenomic approach. Gut 55:205-211.[Abstract/Free Full Text]
5 - Ott, S. J., M. Musfeldt, K. N. Timmis, J. Hampe, D. F. Wenderoth, and S. Schreiber. 2004. In vitro alterations of intestinal bacterial microbiota in fecal samples during storage. Diagn. Microbiol. Infect. Dis. 50:237-245.[CrossRef][Medline]
6 - Ott, S. J., M. Musfeldt, U. Ullmann, J. Hampe, and S. Schreiber. 2004. Quantification of intestinal bacterial populations by real-time PCR with a universal primer set and minor groove binder probes: a global approach to the enteric flora. J. Clin. Microbiol. 42:2566-2572.[Abstract/Free Full Text]
7 - Ott, S. J., M. Musfeldt, D. F. Wenderoth, J. Hampe, O. Brandt, U. R. Fölsch, K. N. Timmis, and S. Schreiber. 2004. Reduction in diversity of the colonic mucosa associated microflora in patients with active inflammatory bowel disease. Gut 53:685-693.[Abstract/Free Full Text]
8 - Schroeder, K. W., W. J. Tremaine, and D. M. Ilstrup. 1987. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317:1625-1629.[Abstract]
9 - Schryver, J. C., C. C. Brandt, S. M. Pfiffner, A. V. Palumbo, A. D. Peacock, D. C. White, J. P. McKinley, and P. E. Long. 2006. Application of nonlinear analysis methods for identifying relationships between microbial community structure and groundwater geochemistry. Microb. Ecol. 51:177-188.[CrossRef][Medline]
10 - Seksik, P., L. Rigottier-Gois, G. Gramet, M. Sutren, P. Pochart, P. Marteau, R. Jian, and J. Dore. 2003. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 52:237-242.[Abstract/Free Full Text]
11 - Sepehri, S., R. Kotlowski, C. N. Bernstein, and D. O. Krause. 2007. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm. Bowel Dis. 13:675-683.[CrossRef][Medline]
12 - Wilson, K. H., and R. B. Blitchington. 1996. Human colonic biota studied by ribosomal DNA sequence analysis. Appl. Environ. Microbiol. 62:2273-2278.[Abstract]
13 - Zoetendal, E. G., A. von Wright, T. Vilpponen-Salmela, K. Ben-Amor, A. D. Akkermans, and W. M. de Vos. 2002. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl. Environ. Microbiol. 68:3401-3407.[Abstract/Free Full Text]
Journal of Clinical Microbiology, October 2008, p. 3510-3513, Vol. 46, No. 10
0095-1137/08/$08.00+0 doi:10.1128/JCM.01512-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.